ISRCTN80109258已完成未知
Peroxisome proliferator-activated receptor gamma (PPAR-gamma): a novel therapeutic target for asthma? A randomised double-blind placebo-controlled clinical trial.
niversity of Nottingham (UK)0 个研究点目标入组 100 人开始时间: 2010年4月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged 18 - 75 years, of either sex, with a clinical diagnosis of asthma
- •2. Forced expiratory volume in one second (FEV1) greater than or equal to 60% predicted and an increase in forced expiratory volume in one second (FEV1) of greater than 12% following inhaled salbutamol 400 µg or peak flow variability greater than 12% during run in
- •3. Permitted medication, 0 - 800 µg inhaled beclomethasone diproprionate or equivalent and a short acting beta-2-agonist as required
排除标准
- •1. Inability to produce a sputum sample on induction
- •2. Currently smoking
- •3. Greater than 10 pack years smoking history
- •4. Treatment with leukotriene antagonists
- •5. Long-acting beta agonists or theophylline
- •6. Liver or cardiovascular disease
- •7. Oral steroid treatment or exacerbation within 6 weeks
- •8. Females who are pregnant, lactating or not using adequate contraception
- •9. Any contra-indication to pioglitazone (hypersensitivity to pioglitazone, cardiac failure, history of cardiac failure, hepatic impairment, diabetic ketoacidosis)
- •10. Oral or insulin treatment for diabetes
- •11. Treatment with gemfibrozol or rifampicin
研究者
相似试验
进行中（未招募）
1 期
The use of Peroxisome Proliferator Activator Receptor Agonists in the management of Androgen Independent Prostate Cancer - PPAREUCTR2006-001398-44-GBBarts and The London NHS Trust49
进行中（未招募）
不适用
The effect of peroxisome proliferator activator receptor ? agonist pre-treatment on pegylated interferon-a2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegylated interferon and ribavirin - a randomized-controlled trial - - HEPAR studyChronic hepatitis C infectionMedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2007-007075-16-NLVU university medical center50
撤回
不适用
The effect of peroxisome proliferator activator receptor * agonist pre-treatment on pegylated interferon-*2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegylated interferon and ribavirin - a randomized-controlled trialViral liver disease1001965410047438Hepatitis CNL-OMON31787Vrije Universiteit Medisch Centrum50
已完成
不适用
Can the use of the Peroxisome Proliferator-Activated Receptor (PPAR)-gamma agonist rosiglitazone reverse the abnormal distribution of fat, as well as disturbances in glucose and lipid metabolism in Human Immunodeficiency Virus (HIV)-associated lipodystrophy syndrome?Human Immunodeficiency Virus (HIV)-associated lipodystrophy syndromeInfections and InfestationsHuman Immunodeficiency VirusISRCTN78808170Academic Medical Centre (AMC) (The Netherlands)15
已完成
4 期
Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis PatientsEnd-stage Renal DiseaseNCT00745225The University of Hong Kong160